ישראל - עברית - Ministry of Health

unipharm ltd, israel - donepezil hydrochloride - טבליה - donepezil hydrochloride 10 mg - anticholinesterases - treatment of mild to moderately severe alzheimer`s dementia.

ישראל - עברית - Ministry of Health

unipharm ltd, israel - donepezil hydrochloride - טבליה - donepezil hydrochloride 5 mg - anticholinesterases - treatment of mild to moderately severe alzheimer`s dementia.

ישראל - עברית - Ministry of Health

רות גינדי קוסמטיקה ויופי - איפור וצביעת העור

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - haloperidol - טבליה - haloperidol 10 mg - haloperidol - haloperidol - management of psychotic disorders . control of tics and vocal utterances of tourette's disorder in children and adults.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - haloperidol - טבליה - haloperidol 0.5 mg - haloperidol - haloperidol - management of psychotic disorders control of tics and vocal utterances of tourette's disorder in children.

ישראל - עברית - Ministry of Health

cts chemical industries ltd, israel - haloperidol - טבליה - haloperidol 5.00 mg - haloperidol - haloperidol - management of psychotic disorders. control of tics and vocal utterances of touratte's disorder in children and adults.

ישראל - עברית - Ministry of Health

נאוטק קבוצת קורדן בעמ - הרגעת עור מגורה אצל ילדים

ישראל - עברית - Ministry of Health

pfizer pharmaceuticals israel ltd - sirolimus - תמיסה (פומי) - sirolimus 1 mg/ml - sirolimus - sirolimus - rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. it is recommended that rapamune be used initially in combination with cyclosporine microemulsion and corticosteroids for 2 to 3 months. rapamune may be continued as maintenance therapy with corticosteroids only if cyclosporine can be progressively discontinued.

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 1000 iu / 0.5 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob

ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 2000 iu / 1 ml - erythropoietin - erythropoietin - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients:- treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.- treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis. treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre existing anaemia at the start of chemotherapy). binocrit can be used to increase the yield of autologous blood from patients in a predonation programme. its use in this indication must be balanced against the reported risk of thromboembolic events. treatment should only be given to non-iron deficient patients with moderate anaemia (haemoglob